AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
- LongGame launches a $40 million venture fund to advance longevity biotechnology with a focus on stem cell research, gene editing, and senolytics.
- The initiative bridges biotechnology and decentralized science, utilizing DAOs to enhance drug discovery and patient-driven research.
- The leadership team at LongGame brings expertise from various sectors of biotechnology, ensuring a comprehensive approach to human longevity.
LongGame, a new venture capital fund, has emerged with the aim of advancing the field of longevity biotechnology. Founded by crypto investor Will Harbone, the $40 million fund is designed to support innovative biotechnologies that could extend human life by decades. The fund’s focus is on transformative areas of biotechnology such as stem cell research, gene editing, and senolytics, all of which are considered crucial in the effort to extend healthy lifespans.
LongGame targets early-stage biotech startups, specifically those that are at the pre-seed or seed stages. By focusing on these early phases, the fund hopes to accelerate the development of scalable technologies that could have significant long-term impacts on human health.
The Role of Decentralized Science in Longevity Research
One of the unique aspects of LongGame’s approach is its emphasis on decentralized science (DeSci). The fund plans to bridge traditional biotechnology and decentralized technologies, particularly through the use of decentralized autonomous organizations (DAOs). These DAOs are designed to streamline drug discovery processes and encourage a more patient-driven research model, potentially reshaping the way biotech industries operate. By integrating decentralized tools, LongGame aims to reduce barriers to innovation and improve access to cutting-edge longevity treatments.
The collaboration between biotechnology and decentralized platforms could unlock new possibilities for how research is conducted and how treatments are developed, opening the door for more personalized and accessible medical solutions.
Expert Leadership Team
LongGame's leadership team brings a wealth of experience in both biotechnology and blockchain technology. The team is led by Will Harbone, with COO Chloe Northcott, previously of Geometry, and Special Advisor Sebastian A. Brunemeier, General Partner at Healthspan Capital, contributing their expertise to the fund. Dr. Manish Chamoli serves as the Chief Scientific Officer, bringing deep knowledge of aging biology and longevity from his work at the Buck Institute.
The leadership team’s combined expertise in longevity research and decentralized technologies positions LongGame to play a pivotal role in advancing both fields, collaborating with specialists from various sectors to bring cutting-edge solutions to market.
Strategic Funding and Future Goals
Over the next several years, LongGame plans to strategically allocate capital to companies that align with its mission to extend healthy human lifespans. By focusing on scalable biotech startups and integrating decentralized science, LongGame aims to support a wide range of advancements in health and medicine. The fund’s goal is not just to support innovation but also to foster global scalability for its portfolio companies, ensuring that breakthroughs in longevity biotechnology have the potential to reach a global audience.
As the biotech landscape continues to evolve, LongGame's approach of combining traditional science with decentralized technologies may lead to new, revolutionary advancements in human health and longevity.
